Product Details
| Product Name: Vonoprazan Fumarate | CAS No.: 1260141-27-2 |
| Min. Order: 2KG | Purity: 99% min/GMP/PMDA/DMF |
| Supply Ability: 20tons | Release date: 2026/06/03 |
Product Information


COA of Vonoprazan Fumarate

Usage
Function of Vonoprazan Fumarate
1) Prevention of duodenal ulcer and gastric ulcer recurrence
A randomized, double-blind, multi-center clinical phase 3 trial comparing the effects of Voronazan fumarate (10mgqd and 20mgqd) and lansoprazole (15mgqd) on nonsteroidal anti-inflammatory drug-related peptic ulcer A total of 642 patients had been diagnosed with endoscopic peptic ulcers and needed to take non-steroidal anti-inflammatory drugs. The treatment period was 24 weeks. The primary endpoint was the proportion of duodenal ulcer and gastric ulcer recurrence at 24 weeks.
2) Corrosive esophagitis (erosiveoesophagitis, EO)
In a randomized, double-blind, multi-center, dose-range clinical phase 2 trial, in patients with EO, compared with lansoprazole, Voronazan fumarate showed non-inferiority and was rated in Los Angeles as C/D grade patients showed excellent effects, and oral administration of 20 mg once daily became the clinically recommended dose for the treatment of EO. A randomized, double-blind, multi-center clinical phase 3 trial comparing the efficacy of this product (20mgqd) and lansoprazole (30mgqd) on EO, a total of 409 patients participated in the study.
3) Helicobacter pylori infection (Helicobacterpylori, Hp)
A randomized, double-blind, multi-center clinical phase 3 trial comparing vonolazan fumarate (20mgbid) and lansoprazole (30mgbid), combined with amoxicillin and clarithromycin, to form a triple therapy, The effect of first-line medicine to eradicate Hp was included in a total of 650 Hp-positive patients who had had gastric ulcer or duodenal ulcer. The Hp eradication rates of this product and lansoprazole in the test group were 92.6% and 75.9%, respectively. For patients with clarithromycin resistance, the Hp eradication rates in the two test groups were 82.0% and 40.0%, respectively. Significantly superior to lansoprazole. In this trial, the first 50 patients who failed first-line treatment received second-line treatment with triple therapy of this product, amoxicillin and metronidazole, and the Hp clearance rate was 98%.

Company Profile Introduction
You may like
-
CAS:111974-72-2
-
CAS:202138-50-9
-
CAS:183814-30-4
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-04 | ||
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-06-03 | ||
|
VIP1Y
|
Henan Boweixin Biotechnology Co., Ltd.
|
2026-05-29 | ||
|
VIP2Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-05-20 | ||
| $50.00 |
VIP3Y
|
Zibo Hangyu Biotechnology Development Co., Ltd
|
2026-05-05 | |
|
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-04-22 | ||
| $5.00 |
Wuhan JiyunZen Tech Co., Ltd.
|
2026-04-10 | ||
|
VIP4Y
|
shandong perfect biotechnology co.ltd
|
2026-03-27 | ||
|
VIP6Y
|
AFINE CHEMICALS LIMITED
|
2026-03-27 | ||
| $1.00 |
Hebei Chuanghai Biotechnology Co., Ltd
|
2026-03-20 |
- Since: 1996-07-16
- Address: 16F,HUICHENG COMM,839 XIAHE ROAD,XIAMEN CHINA

China